Vancomycin: does it still have a role as an antistaphylococcal agent? (Q36839712)

16 August 2017

1 reference

title

Vancomycin: does it still have a role as an antistaphylococcal agent? (English)

1 reference

16 August 2017

1 reference

Stan Deresinski

1

1 reference

16 August 2017

publication date

1 June 2007

1 reference

Expert Review of Anti-infective Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

5

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

393-401

1 reference

Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

The changing epidemiology of Staphylococcus aureus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

“Celbenin” - resistant Staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

MRSA--the tip of the iceberg

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Rapid decrease of free vancomycin in dense staphylococcal cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Comparative activity of cloxacillin and vancomycin against methicillin-susceptible Staphylococcus aureus experimental endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Comparison of linezolid activities under aerobic and anaerobic conditions against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Glycopeptide tolerance in Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Inhibition of the autolytic system by vancomycin causes mimicry of vancomycin-intermediate Staphylococcus aureus-type resistance, cell concentration dependence of the MIC, and antibiotic tolerance in vancomycin-susceptible S. aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Serum protein-binding characteristics of vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

The pharmacokinetic and pharmacodynamic properties of vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Intrapulmonary pharmacokinetics of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Effect of vancomycin therapy for osteomyelitis on colonization by methicillin-resistant Staphylococcus aureus: lack of emergence of glycopeptide resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Linezolid eradicates MRSA better than vancomycin from surgical-site infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Are swine workers in the United States at increased risk of infection with zoonotic influenza virus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

In vitro exposure of community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains to vancomycin: does vancomycin resistance occur?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

The importance of bactericidal drugs: future directions in infectious disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

Antistaphylococcal vaccines and immunoglobulins: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

What Can We Learn from Studies Comparing Linezolid with Vancomycin in Neutropenic Patients When Vancomycin Dosages Are Not Optimized?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.393

21 January 2018

Identifiers

DOI

10.1586/14787210.5.3.393

1 reference

release_dhyghbpuyfdfdpmgndsljy6cbi

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dhyghbpuyfdfdpmgndsljy6cbi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference